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Abstract
Ever declining autopsy rates have been a concern of pathologists as well as clinicians for decades. Notably, in the field of
oncology, data on autopsies and discrepancies between clinical and autoptic diagnoses are particularly scarce. In this
retrospective study, we show the effect of a simple catalog of measures consisting of a different approach to obtain consent
for autopsy, structured conferencing, and systematic teaching of residents, as well as a close collaboration between
clinicians and pathologists on the numbers of autopsies, especially of oncological patients. Additionally, postmortem
examination protocols from the years 2015 until 2019 were analyzed, regarding rates of discrepancies between clinical
and autoptic causes of death in this category of patients. Autopsy numbers could be significantly increased from a
minimum in 2014 (60 autopsies) to a maximum in 2018 (142 autopsies) (p < 0.0001). In the 67 autopsies of oncological
cases, a high rate of 51% of major discrepancy between clinical and autoptic causes of death could be detected. In contrast
to the general reported decline of autopsy rates, we present rising autopsy numbers over the past 5 years with an increasing
number of oncological cases who underwent a postmortem examination. The high percentage of major discrepancies
between clinical and autopsy diagnosis is in contrast to an expected decrease of major discrepancies in times of precise
diagnostic methods and underlines the importance of autopsies to ensure high quality in diagnostics and therapy not only
in the field of oncology.
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Introduction
Autopsy rates have been decreasing for several decades.
Although general registries for autopsy rates are lacking, de-
clining numbers of postmortem examinations have been re-
ported in numerous publications. In Germany, a decline in
overall numbers of autopsies of 30% between 2005 and 2014
was detected [1]. This number is concordant with previous
reports from other countries such as France, Sweden, and the
USA where the decline has been reported to be even more
severe [2, 3]. A survey among pathologists in Germany re-
vealed an autopsy rate of patients who died in a hospital of
3.63% in 2013 and 3.39% in 2014 [4]. Numerous reasons are
quoted for the decline. Besides costs and cultural reasons, dif-
fering working patterns of pathologists with focus on surgical
pathology and considerations about the necessity of postmor-
tem examinations in times of improved radiological and endo-
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in autopsy numbers is not only a recent phenomenon. Already
in 1983, declining autopsy rates were attributed to diagnostic
progress, resulting in a presumably decreasing rate of discrep-
ancies between clinical judgment and autopsy findings. Of
note, however, this decline in discrepancies was not detectable
in a large analysis by Goldman et al. [8]. In the subsequent
almost 30 years, medical progress has accelerated consider-
ably. In recent publications however, the rate of major discrep-
ancies remains considerably high with 19.5–28% [3, 9–11]. In
oncological patients, detailed studies of postmortem examina-
tions are lacking. The few existing investigations aremainly on
cancer patients who died at intensive care units and show rates
of major discrepancies between 26 and 59% [12, 13]. In this
retrospective analysis, we want to demonstrate how low autop-
sy rates can be increased by optimized structured interaction of
pathologists and clinicians. Furthermore, we want to evaluate
the relevance of autopsies of oncological patients.
Methods
Means to increase autopsy rates
In 2015, at the beginning of the analyzed period, a catalog of
measures was established in the II. Department of Internal
Medicine in order to increase the number of autopsies.
Deaths had to be reported in the morning meeting the next
day. Residents were instructed with regard to structured con-
versations with relatives. This instruction took place a first
time in 2015 and was repeated regularly afterwards in the
morning conferences in association with the discussion of
decedents and the consent to autopsy. Furthermore, a demon-
stration of autoptic findings to clinicians took place after every
autopsy and a weekly demonstration of relevant cases was
given by the pathologists in front of the whole team of the
II. Department of Internal Medicine.
Analysis of oncological cases
Annual autopsy numbers of adult patients of the past decade
were retrieved from the local database at University Medical
Center Augsburg. Patients who died in the II. Department of
Internal Medicine, which comprises hematology and medical
oncology as well as nephrology and an intensive care unit,
from January 2015 to October 2019 were screened for known
and active oncological diagnoses at the time of death by
checking the medical record. Incomplete autopsies as well as
incidentally found and not previously suspected tumor diag-
noses were excluded. Of the remaining cases, demographic
data, oncological diagnoses, clinically assumed cause of
death, the specific question of clinicians to pathologists for
autopsy, and the autoptically revealed cause of death were
retrieved from the postmortem examination protocol. The
information on the clinical cause of death were reported in
the autopsy protocol according to the death certificate, the
medical information in the autopsy request and the physician’s
letter. Additionally, the treating clinician gave an overview of
the case in the course of the presentation of the autoptic find-
ings. In unclear cases, the electronic file of the patient was
consulted by the authors. The cause of death revealed by au-
topsy was separated into immediate cause of death, underlying
diagnoses, and basic diagnoses in the autopsy protocol. For
our analysis however, only the immediate cause of death was
considered. If necessary, the reported results were interpreted
by the authors to state one immediate cause of death.
Subsequently, discrepancies between clinical and autoptic di-
agnosis were categorized according to the discrepancy criteria
displayed in Table 1. In the special situation of oncological
patients, every major diagnosis was individually assessed for
its treatability and therefore classified as class I or class II
discrepancy. For each case, the highest level of discrepancy
was recorded as well as further levels of discrepancy if appli-
cable. Unclear cases were discussed with the head of the
Department of Pathology and Molecular Diagnostics (BM).
Only diagnoses that were detected or confirmed during autop-
sy were taken into account. Therefore, false-positive clinical
diagnoses were not included. Main diagnoses were catego-
rized into seven thematic fields: infection/ sepsis, embolism,
cardiac failure (comprising deaths of ischemic cardiac failure
and non-ischemic cardiac failure, for example, deaths of hy-
pertensive heart disease, arrhythmic events, or pericardial
tamponade), tumor (for example, spreading to vital organs
or perforation of hollow organs due to the tumor), bleeding,
others (for example, liver failure as a result of the tumor ther-
apy, ileus, thrombotic microangiopathy), and unknown cases.
The study was approved by the local medical ethical
committee (institutional review board, reference number
BKF 2019/35).
Statistical analyses were performed with SigmaPlot 13.0
(Systat, Erkrath, Germany) and Microsoft Excel (Microsoft
Office 16). Chi-square test was used to compare frequen-
cies of major discrepancies between male and female as
well as old and young patients, patients who did or did
not receive immunotherapy, and between early years of
analysis and later years. Two tailed t-test was performed
for comparing continuous normally distributed data. A P
value of <0.05 was considered significant.
Results
Increase of autopsy numbers
Annual autopsy numbers varied between 60 and 93 in the
years 2010 until 2017 and showed a significant increase
(p < 0.0001) in 2018 and 2019, with 142 and 137
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postmortem examinations performed at the University
Medical Center Augsburg. Of these, the fraction of autop-
sies of patients who died in the II. Department of Internal
Medicine rose from 0% in 2010 to 35.8% in 2019. The
total number of patients who deceased in the University
Medical Center of Augsburg during this time period varied
between 1.850 and 2.083 per year with a median of 1963.
The overall autopsy rate was calculated with a minimum of
3.1% in 2014 and a maximum of 7.3% in 2018. Numbers
and rates of autopsies of the years 2010–2019 are shown in
Fig. 1.
Results of oncological autopsies
Between January 2015 and October 2019, a total of 517
autopsies were performed in the Department of Pathology.
Of these, 120 were cases that were previously treated at the
II. Department of Internal Medicine and in 76 of these, a
tumor diagnosis was reported in the medical record. After
removing cases in which the tumor diagnosis was not
known before and made incidentally during the postmor-
tem examination and incomplete autopsies of for example
only bone marrow or brain, 67 cases of patients with a
Table 1 Classification of discrepancies according to Goldman [8] and Battle [14]
Level of discrepancy Description Example
Major discrepancy Class I Missed treatable primary diagnosis with
direct correlation to cause of death.
Detection and treatment would
in all probability have led to
prolonged survival.
Missed myocardial infarction without
cardiac arrest or undetected
gastrointestinal bleeding with
therapeutical option.
Class II Missed primary diagnosis with unclear
impact on survival. Detection would
probably not have resulted in a changed
treatment (for example because of
lacking treatment options).
Perforation of the stomach without
therapeutical option or unknown
spreading of the tumor to vital organs
under tumor therapy.
Minor discrepancy Class III Missed secondary diagnosis with no direct
correlation to cause of death but
symptoms that would have indicated
treatment. Detection and treatment
would probably have an impact
on prognosis.
Unknown arteriosclerosis or old myocardial
infarction without prior treatment.
Class IV Missed secondary occult diagnosis with no
indication for treatment but of possible
genetic or epidemiological importance.
Asymptomatic cholecystolithiasis or struma.
Class V No discrepancy.
Class VI Unclear cases.
Fig. 1 Numbers and rates of
autopsies conducted between
2010 and 2019 at the University
Medical Center Augsburg
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known and active tumor disease were eligible for the anal-
ysis (Fig. 2).
Demographic and disease characteristics are shown in
Table 2 . The median age was 67 (24–93) years.
Interestingly, 48 (72%) patients were male and 19 (28%) fe-
male (p = 0.028). The most frequent tumor entities were of the
blood and lymphatic system (37%) and of the lung (22%). In
total, 84% of the patients had died at an advanced tumor stage
and 10% of the patients had been previously treated with an
immunotherapy.
The clinically assumed cause of death was infection with
sepsis in the majority of cases which was consistent with
autoptic findings. Embolism, tumor-associated causes of
death, and cardiac failure were more frequently found in post-
mortem examinations than clinically suspected (Table 3).
The specific question addressed to the pathologist was
“cause of death” in 48% of cases, followed by questions
concerning the tumor disease like specific histology or tumor
extension/stage.
For each case, the highest level of discrepancy was docu-
mented. In 51% of autopsies, major discrepancies between
clinical and postmortem assessment were detected (18% class
I and 33% class II). Only in 8% of cases, neither major nor
minor discrepancy was found (Fig. 3). The most frequent un-
detected diagnoses that were classified as class I discrepancy
were infection/sepsis (n = 6) and pulmonary embolism (n = 4).
Table 4 gives an overview of the clinical and autoptic cause of
death of the 12 patients with a class I discrepancy. Undetected
diagnoses that were classified as class II discrepancy included
infection/sepsis (n = 6), cardiac failure (n = 6), tumor-related
diagnoses (n = 6), embolism (n = 2), and others (n = 2).
Figure 4 shows exemplary cases for discrepancies class I
and class II.
Regarding secondary findings, the most frequent class III
discrepancies were arteriosclerosis (n = 9), pulmonary
emphysema (n = 8) and small or old myocardial infarctions
(n = 4). The most frequent class IV discrepancies were struma
(n = 12), benign changes of the female genital tract like uterus
myomatosus or fibroma/ cystadenoma of the ovary (n = 7),
and diverticulosis (n = 7).
In comparing frequencies of major discrepancies between
male and female patients, no significant difference could be
detected using chi-square test (p = 0.15). Likewise, no signif-
icant difference of major discrepancies could be found in
younger and older patients (p = 0.38), in earlier years with
lower autopsy rates (2015–2017) compared to later years with
increased autopsy rates (2018/2019) (p = 0.54), in patients
with advanced tumor disease compared to patients with limit-
ed disease (non-metastatic, no local invasion of surrounding
tissue) (p = 0.35) or in patients who did or did not receive
immunotherapy (p = 0.72).
Discussion
Effect of the measures to increase autopsy rates
In contrast to the generally reported decline of autopsy num-
bers, increasing rates of autopsies could be seen at the
University Medical Center Augsburg since 2017. These were
mostly attributed to a rising number of patients premortally
treated at the II. Department of Internal Medicine including
oncological cases. The increase of autopsy numbers could be
achieved with a simple catalog of measures as described in the
“Methods” part. As main reasons for the successful change in
autopsy policies, an increased awareness of the topic, as well
as an intensive cooperation between clinicians and patholo-
gists not only in everyday work but also in research and teach-
ing, can be named. The motivation of clinical residents of the
II. Department of Internal Medicine to address the topic of
Fig. 2 Selection process of
oncological cases
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postmortem examinations with patients and relatives could be
augmented. Furthermore, the manner in which the topic was
addressed changed from an open question to a precise propos-
al with explanations regarding the benefits of an autopsy. The
fact that communication with patients and relatives plays an
important role to establish a positive view on autopsies and to
obtain consent for the procedure was shown by Rosenberg
et al. [15]. In this study, motivational interviewing of patients
and relatives led to a significant increase of postmortem ex-
aminations. The quality of interaction between clinicians and
pathologist as an approach to higher autopsy numbers was
described previously by Champ et al. who identified regular
meetings between pathologists and clinicians and a positive
attitude towards the other discipline respectively, to play an
important role [16]. In our institution, the combination of both
named approaches resulted in a significant increase of post-
mortem examinations. An additional concept to increase au-
topsy numbers has been proposed by Van den Tweel and
Wittekind, suggesting the creation of “autopsy pathology as
a subspecialty” to overcome the problem of work overload for
pathologists and the problem of late and in parts also insuffi-
cient reporting of postmortem examinations [6].
Relevance of autopsies in oncological patients
Regarding the demographic data of the deceased patients, a
significantly higher number of male patients underwent a
postmortem examination. These findings are consistent with
previous publications [3]. According to Cameron et al., the
reason for higher autopsy rates in male patients is the higher
likelihood of female relatives to give the permission for a
postmortem examination [17].
Themost frequent question to the pathologist in our studywas
“cause of death” with 48%, followed by questions with relation
to the tumor disease. Previous studies analyzing questions ad-
dressed to postmortem examinations are scarce. In a study by
Zarbo et al., “cause of death” was the question in 21% and
tumor-specific questions were asked only in 2% of cases [18].
However, it has to be taken into account that the population of
this study comprised various primary diagnoses while in our
study population every patient had an oncological diagnosis.
In this retrospective analysis, a considerably high number
of major discrepancies between clinical and postmortem diag-
noses could be found. In previous studies and reviews, rates
for major discrepancies varied between 4.1 and 49.8% with
the highest rates in postoperative patients [19]. An assumed
decline of discrepancy rates over the years due to improved
premortal diagnostic technical potential could not be verified
Table 3 Comparison of clinical and autoptic immediate cause of death
Clinical cause of death Autoptic cause of death
Infection/ Sepsis Embolism Cardiac failure Tumor Bleeding Other Unknown
Infection/sepsis (n = 23) 18 1 0 1 0 1 2
Embolism (n = 4) 0 1 1 0 0 1 1
Cardiac failure (n = 2) 0 0 0 2 0 0 0
Tumor (n = 7) 0 1 1 4 0 0 1
Bleeding (n = 2) 0 0 0 0 2 0 0
Other (n = 15) 2 1 0 3 0 9 0
Unknown (n = 16) 4 2 5 2 1 1 1
Table 2 Demographic and disease characteristics
Variables Results
Age; median (range) 67 (24–93)
Sex
Male; n (%) 48 (72)
Female; n (%) 19 (28)
Tumor type
Gastrointestinal tract; n (%) 4 (6)
Liver/gall bladder/pancreas; n (%) 6 (9)
Urogenital tract; n (%) 5 (7)
Female genital tract; n (%) 1 (1)
Breast; n (%) 5 (7)
Blood/lymphatic; n (%) 25 (37)
Head and neck; n (%) 2 (3)
Lung; n (%) 15 (22)
Skin/melanoma; n (%) 4 (6)
Brain; n (%) 1 (1)
Other; n (%) 1 (1)
Stage
Advanced; n (%) 56 (84)
Limited; n (%) 11 (16)
Immunotherapy
Yes; n (%) 7 (10)
No; n (%) 60 (90)
305Virchows Arch (2021) 478:301–308
by Goldman et al. in 1983 [8] and in further analyses compar-
ing different time periods [20, 21]. In contrast, a systematic
review by Shojania et al. described a decline of major discrep-
ancies of 19.4% per decade in 53 autopsy series over 40 years.
The authors explained the difference between lacking declines
in single institution analyses and clear reduction of discrepan-
cies in their review with the insufficient power of the single-
center studies and stricter selection of cases in times of declin-
ing autopsy rates [19]. In the relatively short time period con-
sidered in our study, no significant difference of major dis-
crepancy rates between the earlier years (2015–2017) and later
years (2018 and 2019) could be seen.
In addition to the time period in which an autopsy was
performed, decreasing autopsy rates were linked to higher
discrepancy rates in the mentioned review [19]. The consid-
eration that increased autopsy rates lead to lower selection bias
towards unclear cases could serve as a possible explanation
for this observation. This phenomenon, however, could not be
observed in our study population where the numbers of class I
and II discrepancies showed no significant change in the years
with higher autopsy rates.
Gender and age of decedents did not play a role for the
frequency of major discrepancies in our study. Previous stud-
ies come to different results when regarding the influence of
Table 4 Clinical and autoptic causes of death of patients with class I discrepancy.NSCLC non-small cell lung cancer,CMML chronic myelomonocytic
leukemia, AML acute myeloid leukemia
Nr. Tumor entity Clinical cause of death Autopsy cause of death
3 NSCLC undifferentiated Unknown Pneumonia, sepsis
5 NSCLC poorly differentiated, Unknown, reduced vigilance Myocardial infarction (previously unknown
coronary heart disease) with
cardiovascular failure
13 CMML Pneumonia Septic/toxic cardiovascular failure, due to
superinfection of skin lesions; previous
myocardial damage due to 2–4 weeks old
myocardial infarction
14 Multiple Myeloma Unknown Septic/toxic cardiovascular failure with multiple
septic spots of unknown origin in the lung
15 Mamma carcinoma Unclear sedation and seizure Septic shock with multiorgan failure
due to pneumonia
17 Merkel cell carcinoma Aspiration Pulmonary embolism, central occlusion of the
left pulmonary artery
20 Seminoma Unknown Upper gastrointestinal bleeding due to duodenal
ulcer due to Mycosis
29 Pancreas carcinoma Pneumonia, hematuria Respiratory failure due to multiple pulmonary
embolisms with right heart overload
33 AML Respiratory failure or cerebral bleeding Sigma diverticulosis with abscessed
inflammation and urinary bladder fistula
35 Cholangiocellular carcinoma Multiorganfailure due to tumor progression Bilateral pulmonary embolism with
right heart overload
45 Prostate carcinoma Sepsis, acute kidney failure Pulmonary embolism with right heart overload
57 Small cell carcinoma of the liver Pneumonia Aortal valve endocarditis with sepsis
Fig. 3 Highest documented level of discrepancy between clinical and
autoptic diagnosis. Class I and II: major discrepancies. Class III and IV:
minor discrepancies. Class V: no discrepancy. Class VI: unclear cases
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gender and age on the rate of discrepancies [9, 14, 18, 22, 23].
When a difference in the frequency of discrepancies was de-
tected, more discrepancies were found in older patients and in
women [14, 22, 23]. In addition to gender and age, a preceding
immunotherapy was analyzed for its influence on the occur-
rence of major discrepancies. As this kind of therapy is rela-
tively new and not all side effects may be totally understood, it
would not have been surprising if in patients who received an
immunotherapy, a higher rate of discrepancies could have
been noticed. This, however, was not the case. The number
of patients who underwent an immunotherapy before death
was relatively low (n = 7) though.
The selection of patients might serve as a possible expla-
nation for the high number of major discrepancies in our
study. Autopsies of oncological patients came to the focus of
interest for research purpose in the 1990s. Such research au-
topsies aim to elucidate questions on tumor metastases and
evolutionary biology of cancer, among others [24].
Regarding clinical autopsies, there are only few studies deal-
ing with postmortem examinations in oncological cases and
most of them only included cancer patients who died at an
intensive care unit. Major discrepancy rates of 21–59% were
reported in this collective [12, 25] which is more or less com-
parable to the rates of our study. At the end of a cancer pa-
tient’s life, the extent to which diagnostic procedures are used
might be smaller compared to other collectives. Nevertheless,
the detected high rates of major discrepancies should at least
make clinicians sensitive for the risk of overlooking relevant
diagnoses. On the other hand, every case has to be considered
separately and in the interest of the patient, invasive proce-
dures should sometimes be avoided.
Our data emphasize the persisting value of postmortem
investigations. Despite an obviously continuously improving
diagnostic machinery, important clinical aspects remain unde-
tected in a considerable rate of cases.Moreover, our data show
that a significant increase in autopsy rates is achievable by
intensive and structured cooperation between clinicians and
pathologists and increasing the motivation of the physicians
in obtaining consent for an autopsy.
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